EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients

Khaled Alsabbagh Alchirazi iD, Osama Hamid, Thabet Qapaja iD, Mohammad Aldiabat, Nour Azzouz, Motasem Alkhayyat, Miguel Regueiro iD

Crohn's & Colitis 360 · 10.04.2025 · 7 (2)

DOI: 10.1093/crocol/otaf021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 16.03.2025. Verfasst von Khaled Alsabbagh Alchirazi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Aurora Health Care, Milwaukee, WI, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although traditionally associated with White European ancestry, inflammatory bowel disease (IBD) has increased among different races and ethnicities. Large studies conducted in the United States and Canada have identified more complex disease phenotypes among Black patients. Our study aimed to investigate disparities in IBD treatments and outcomes between Black and White patients in the United States.

Methods

Using the TriNetX database, adult IBD patients were divided into 2 groups based on race: Black and White patients with IBD, Crohn’s disease (CD), or ulcerative colitis (UC). Medical therapy and disease outcomes were evaluated in both groups with 1:1 propensity-score matching. Methodologic limitations include the potential for missing data, lack of information on socioeconomic strata, and patient-level medication coverage plans.

Results

In comparison to White patients, Black patients with CD were less likely to receive advanced therapies; Adalimumab (adjusted odds ratio- aOR 0.89), Certolizumab (0.81), Vedolizumab (0.66), Ustekinumab (0.82), or Tofacitinib (0.58). Black patients with UC were less likely to receive advanced therapies; Adalimumab (0.83), Golimumab (0.62), Vedolizumab (0.69), Ustekinumab (0.73), or Tofacitinib (0.55). Black patients with IBD were at higher odds of utilizing corticosteroids (CD 1.18 and UC 1.20) and opioids (CD 1.26 and UC 1.09). Black patients with CD had higher rates of hospitalization (1.35) and perianal abscess (1.56), perianal fistula (1.28), and intestinal fistula (1.38). Black patients with UC had higher rates of hospitalization (1.29), Clostridioides difficile infection (1.11), and toxic megacolon (1.34).

Conclusions

There were racial disparities in IBD medical therapy and disease outcomes. Black IBD patients had lower treatment with advanced therapies, higher opioid and corticosteroid use, and higher IBD-related complications.

Schlagwörter

Stichwörter der Autor:innen

African AmericanBlackCrohn’s diseaseinflammatory bowel diseaseraceracial disparityulcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology, Aurora Health Care, Milwaukee, WI, USA.
  • Department of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Hospital Medicine, Washington University in St. Louis, St. Louis, MO, USA.
  • Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN, USA.

ORCID-Profile: Khaled Alsabbagh Alchirazi, Thabet Qapaja, Miguel Regueiro

Zitieren

APA

Alsabbagh Alchirazi, K., Hamid, O., Qapaja, T., Aldiabat, M., Azzouz, N., Alkhayyat, M., & Regueiro, M. (2025). Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients. Crohn's & Colitis 360, 7(2). https://doi.org/10.1093/crocol/otaf021

Vancouver

Alsabbagh Alchirazi K, Hamid O, Qapaja T, Aldiabat M, Azzouz N, Alkhayyat M, et al. Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients. Crohn's & Colitis 360. 2025;7(2). doi:10.1093/crocol/otaf021

BibTeX
@article{AlsabbaghAlchirazi2025,
  author = {Alsabbagh Alchirazi, Khaled and Hamid, Osama and Qapaja, Thabet and Aldiabat, Mohammad and Azzouz, Nour and Alkhayyat, Motasem and Regueiro, Miguel},
  title = {Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients},
  journal = {Crohn's & Colitis 360},
  year = {2025},
  volume = {7},
  number = {2},
  doi = {10.1093/crocol/otaf021}
}
Kostenlos starten →